BriaCell Therapeutics R&D spend
BriaCell Therapeutics Corp. · BCT (TSX) · West Vancouver, BC · Pharmaceuticals
Latest R&D (CAD)
$29.7M
Period ended 2025-07-31
Revenue (CAD)
—
— of revenue
R&D by fiscal period
2025
$29.7M
2024
$37.2M
2023
$20.7M
2022
$10.4M
2021
$2.5M
2020
$3.3M
2019
$5.3M
| Period end | R&D (CAD) | Revenue (CAD) | Native R&D | Form | Source |
|---|---|---|---|---|---|
| 2025-07-31 | $29,732,154 | — | $21,270,678 USD | 10-K | SEC EDGAR |
| 2024-07-31 | $37,228,160 | — | $27,177,807 USD | 10-K | SEC EDGAR |
| 2023-07-31 | $20,699,860 | — | $15,336,638 USD | 10-K | SEC EDGAR |
| 2022-07-31 | $10,438,364 | — | $8,021,489 USD | 10-K | SEC EDGAR |
| 2021-07-31 | $2,533,197 | — | $2,020,899 USD | 10-K | SEC EDGAR |
| 2020-07-31 | $3,254,262 | — | $2,425,838 USD | 40-F/A | SEC EDGAR |
| 2019-08-01 | $5,311,151 | — | $4,002,676 USD | 40-F/A | SEC EDGAR |